

[54] **THERAPEUTIC AGENT FOR
CONSCIOUSNESS DISORDER AND
PERCEPTION AND MOVEMENT
DISORDER**

[75] Inventors: **Tadashi Nakajima**, Takatsuki; **Kyoji Rikimi**, Osaka; **Yasuji Soda**, Kobe; **Kenichi Kashima**, Fujiidera; **Akira Miyamoto**, Nishinomiya; **Yoshikazu Soejima**, Osaka, all of Japan

[73] Assignee: **Nippon Shoji Kaisha, Ltd.**, Osaka, Japan

[21] Appl. No.: **146,215**

[22] Filed: **May 5, 1980**

Related U.S. Application Data

[62] Division of Ser. No. 16,340, Feb. 28, 1979, abandoned.

[30] Foreign Application Priority Data

Feb. 28, 1978 [JP] Japan 53/22385

[51] Int. Cl.³ **A23J 7/00; A61K 31/685**

[52] U.S. Cl. **424/199; 260/403**

[58] **Field of Search** 424/199; 260/403

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,772,360 11/1973 Pfeiffer et al. 260/403

Primary Examiner—Stanley J. Friedman

Attorney, Agent, or Firm—Stevens, Davis, Miller & Mosher

[57] **ABSTRACT**

A therapeutic agent for treating consciousness disorder and perception and movement which comprises as an essential active ingredient a phosphatidic acid derivative selected from a phosphatidylcholine, a phosphatidic acid and a phosphatidylethanolamine in admixture with a conventional carrier. Said agent is administered to the patient suffered from consciousness disorder and perception and movement disorder, particularly the post-traumatic syndrome of the head injury and the sequelae of apoplexy or whiplash injury in oral or parenteral route, preferably in an intravenous route.

12 Claims, 20 Drawing Figures